PMX 205
- Product Name
- PMX 205
- CAS No.
- 514814-49-4
- Chemical Name
- PMX 205
- Synonyms
- PMX-205;PMX 205 （TFA）;Hydrocinnamate;deamino-Phe-Orn(1)-Pro-D-Cha-Trp-Arg-(1);L-Arginine, N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-, (5→1)-lactam
- CBNumber
- CB33166333
- Molecular Formula
- C45H62N10O6
- Formula Weight
- 839.04
- MOL File
- 514814-49-4.mol
PMX 205 Property
- Density
- 1.38±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- pka
- 13.40±0.70(Predicted)
- Water Solubility
- Soluble in 20% ethanol / sterile Water
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P321Specific treatment (see … on this label).
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P362Take off contaminated clothing and wash before reuse.
N-Bromosuccinimide Price
- Product number
- 13607
- Product name
- PMX-205
- Purity
- ≥95%
- Packaging
- 500μg
- Price
- $159
- Updated
- 2021/12/16
- Product number
- 13607
- Product name
- PMX-205
- Purity
- ≥95%
- Packaging
- 1mg
- Price
- $254
- Updated
- 2021/12/16
- Product number
- 5196
- Product name
- PMX205
- Packaging
- 1
- Price
- $294
- Updated
- 2021/12/16
- Product number
- 256287
- Product name
- PMX 205
- Packaging
- 1mg
- Price
- $573
- Updated
- 2021/12/16
- Product number
- B7787
- Product name
- PMX205
- Packaging
- 5mg
- Price
- $1051
- Updated
- 2021/12/16
PMX 205 Chemical Properties,Usage,Production
Uses
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
Definition
ChEBI: PMX-205 is a homodetic cyclic peptide resulting from the formal condensation of the carboxy group of N(2)-(3-phenylpropanoyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine with the 5-amino group of the N(2)-acylornithyl residue. It has a role as an antagonist, an anti-inflammatory agent and a C5a receptor antagonist. It is an azamacrocycle and a homodetic cyclic peptide.
in vivo
PMX 205 (PMX205) is an orally active, selective C5aR antagonist. Animals treated with PMX 205 (1 mg/kg/day, oral) displays a significant extension of survival time and a reduction in end-stage motor scores, as compared with vehicle-treated rats. PMX 205-treated animals also display reduced levels of astroglial proliferation in the lumbar spinal cord. SOD1G93A rats are orally dosed with PMX 205 (1 mg/kg/day) from two time points (days 28 and 70) before the onset of major clinical symptoms. Both treatment groups have a significant extension in survival time compared with untreated rats (p=0.022, day 28; p=0.015, day 70), with no clear differences in outcomes between the two treatment regimens[2]. Tg2576 mice are treated with PMX 205 (PMX205) at 20 μg/mL in the drinking water (n=17) from 12 to 15 mo of age, the time frame at which there is a rapid accumulation of amyloid deposits in these animals. Untreated Tg2576 animals (n=11) are used as controls. After 3 mo, animals treated with PMX 205 show significantly less fibrillar plaque load (thioflavine reactivity) than do untreated animals. In 3×Tg mice, PMX 205 also significantly reduces hyperphosphorylated tau (69%)[3].
storage
Store at -20°C
References
[1] Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment. J Cancer Res Ther. 2016 Apr-Jun;12(2):590-6. DOI:10.4103/0973-1482.146066
[2] Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34. DOI:10.4049/jimmunol.181.12.8727
[3] Fonseca MI, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009 Jul 15;183(2):1375-83. DOI:10.4049/jimmunol.0901005
PMX 205 Preparation Products And Raw materials
Raw materials
Preparation Products
PMX 205 Suppliers
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Country
- China
- ProdList
- 3506
- Advantage
- 58
- Tel
- info@creative-peptides.com
- Country
- United States
- ProdList
- 6083
- Advantage
- 56
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 17705183659
- Fax
- 84523390
- sales@njleonbiotech.com
- Country
- China
- ProdList
- 5501
- Advantage
- 55
- Tel
- 0571-87213919
- Eric@peptidego.com
- Country
- China
- ProdList
- 7408
- Advantage
- 58
- Tel
- 15911056312
- liming@bio-fount.com
- Country
- China
- ProdList
- 9729
- Advantage
- 58
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-2135480471
- sales@sarms4muscle.com
- Country
- China
- ProdList
- 10473
- Advantage
- 58
- Tel
- 021-61263389 13524856427
- Fax
- WeChat630417570
- Joetang@glschina.com
- Country
- China
- ProdList
- 10000
- Advantage
- 58
- Tel
- +1-631-485-4226
- Fax
- 1-631-614-7828
- inquiry@bocsci.com
- Country
- United States
- ProdList
- 19552
- Advantage
- 58